Document is current
Any future updates will be listed below
-
Authors
Takahashi, Hiromichi
Ito, Shun
Nakanishi, Yoko
Miura, Katsuhiro https://orcid.org/0000-0002-1538-3804
Nishimaki, Haruna
Nakagawa, Masaru
Otake, Shimon
Hamada, Takashi
Koike, Takashi
Iizuka, Kazuhide
Masuda, Shinobu
Nakayama, Tomohiro
Shimizu, Tetsuo
Ishibashi, Naoya
Kogure, Hirofumi
Nakamura, Hideki
-
Funding
Funding for this research was provided by:
JSPS KAKENHI (JP20K16397)
- License Information
-
More Information
Article History
Received: 22 May 2024
Accepted: 3 January 2025
First Online: 17 January 2025
Declarations
:
: This study was approved by the Nihon University Itabashi Hospital Clinical Research Judging Committee in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects (updated March 2023; approval number RK-210608-9). The committee waived the requirement for informed consent from the patients owing to the retrospective nature of this study.
: H.T. received honoraria from Chugai, Kyowa Kirin, Nippon Shinyaku, Takeda, and Bristol-Myers Squibbs. T.H. received honoraria from Bristol-Myers Squibb. M. N. received honoraria from Bristol-Myers Squibb. K.M. received honoraria from AstraZeneca, Chugai, Kyowa Kirin, Takeda, Bristol-Myers Squibb, Nippon Shinyaku, SymBio, and Ono Parma. H.N. has received research grants from MSD, Asahi Kasei Pharma, Astellas, AbbVie, Japan Blood Products Organization, Eisai, Otsuka Pharmaceutical, Ono Pharma, Kyowa Kirin, Sanofi, Shionogi, Daiichi Sankyo, Taiho, Takeda, Mitsubishi Tanabe, Chugai, Teijin Pharma, Eli Lilly, Nippon Kayaku, Nihon Pharmaceutical, Boehringer Ingelheim, and Pfizer. The authors declare no other conflicts of interest.
